The studies are designed to evaluate the potential of the Hemopurifier to treat West Nile virus (WNV), and to further demonstrate the broad-spectrum effectiveness of the Hemopurifier to capture viral pathogens. The WNV studies will be conducted at the Battelle Biomedical Research Center, a global research organization.
Aethlon Medical considers the Hemopurifier to be the leading broad-spectrum candidate as evidenced by its breadth of preclinical data and human treatment experience. Data resulting from the WNV study and other clinical programs will be included in a forthcoming submission to US Department of Health and Human Services (HHS) and the newly established Biomedical Research and Development Authority (BARDA) to advance the commercialization of the Hemopurifier as a broad-spectrum countermeasure against bioterror and pandemic threats.